BioSpaceOriginal article
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
Phase 3positiveivonescimabPositive
AI Analysis
Summary
Summit Therapeutics and Akeso announced a Phase 3 positive readout for ivonescimab in biliary cancer, demonstrating significant overall survival benefit and marking the first indication beyond non-small cell lung cancer to show such results.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
significant overall survival benefit demonstrated in Phase 3 trial for biliary cancer, first indication beyond non-small cell lung cancer showing OS benefit
Importance:7/10
Sentiment:
0.75
Phase 3Data ReadoutOncologyPD-1/VEGF inhibitorBiliary CancerOverall SurvivalChina
Read the original article
Published by BioSpace on August 26, 2026 1:27 PM